Sign in to follow this  
In The News

Medimetriks Announces that Otsuka Achieved Positive Top-Line Phase 3 Results for MM36 (difamilast) in Japanese Adult and Pediatric Atopic Dermatitis Patients

Recommended Posts

FAIRFIELD, N.J., March 26, 2020 /PRNewswire/ -- Medimetriks Pharmaceuticals, Inc. today announced that its partner, Otsuka Pharmaceuticals Co. Ltd., achieved positive results in two Phase 3 Japanese clinical trials in adult and pediatric patients for MM36 (difamilast), a novel topical,...

View the full article

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Sign in to follow this